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Insulin-like  growth  factor-binding  proteins 
(IGFBPs) are a family of secreted  proteins that bind 
insulin-like  growth  factors I and 11 (IGFs I and 11) and 
are capable of modulating IGF  actions on target cells. 
We have shown previously that C2 myoblasts secrete  a 
single  -29-kDa  IGFBP  during their  terminal  differ- 
entiation (Tollefsen, s. E., Lajara, R., McCusker, R. 
H., Clemmons, D. R., and Rotwein, P. (1989) J. Biol. 
Chem. 264, 13810-13817). In this study, we have 
purified  the  protein  from C2 cell-conditioned media by 
conventional and  IGF-affinity  chromatography, 
cloned its cDNA  by PCR-based and  traditional  library 
screening, and identified it as mouse IGFBP-5. The 
resultant  5561 nucleotide cDNA encodes a  252-amino 
acid mature  protein  (predicted M, -28,400) that  is 97% 
identical to rat and  human IGFBP-5. In  differentiating 
C2 myoblasts and in F3 azamyoblasts the  >6-kilobase 
IGFBP-6 mRNA accumulates concomitantly with  in- 
duction of myogenin  mRNA, an  early  marker of muscle 
differentiation. Ligand blot analysis shows that 
IGFBP-5  protein  is  secreted  within 12 h of the onset 
of differentiation  in these cells and  that  it  is  the only 
IGFBP produced in  several fusing  skeletal muscle cell 
lines. In uiuo, IGFBP-5  transcripts are expressed in a 
variety of mouse tissues including  striated muscle, but, 
unlike  other IGFBPs, it  is  barely detectable  in  liver. 
IGFBP-5 is more conserved than other IGFBPs in 
mammals; its conserved structure  and sequence also 
extends  to non-mammalian vertebrates.  Hybridization 
of a mouse BP5 coding region probe to RNA from 
several chicken andXenopus tissues demonstrated sim- 
ilarly sized transcripts  in  these species. A partial Xen- 
opus cDNA is identical  in 38/45 deduced amino acids 
to  the mammalian proteins. Identification of an IGF- 
binding  protein that  is produced during myoblast dif- 
ferentiation  provides a model system in which to  study 
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the  potential modulatory role of IGFBPs in develop- 
ment. 
Insulin-like growth factors I and I1 (IGF I and 11)’ comprise 
a  related  pair of circulating proteins with pleiotropic effects 
on diverse cell types (reviewed in Refs. 1 and 2). Actions of 
both IGFs are mediated by interaction with the IGF I receptor, 
a  ligand-activated  tyrosine  protein  kinase that is structurally 
similar to  the insulin receptor (3). IGF I1 also binds with high 
affinity to  the IGF I1 receptor. This protein, which is also 
known as  the cation-independent  mannose-6-phosphate 
receptor, plays a major role in lysosomal enzyme targeting, 
although its function in modulating actions of IGF I1 remains 
controversial  (4). IGFs also can bind to a family of secreted 
proteins, termed insulin-like growth factor-binding  proteins 
(IGFBPs), that  are capable of enhancing or inhibiting IGF 
action  in  cultured cells (for review,  see Ref. 5 ) .  
The six IGFBPs that have been identified in mammals have 
a conserved structure that is distinct from the two IGF 
receptors. IGFBPs all contain clusters of similarly placed 
cysteine residues that are located in the NH2 and COOH 
thirds of the proteins.  Different IGFBPs bind IGF I and I1 
with differing affinities, and binding affinity can be altered 
by one or more post-translational modifications, including 
phosphorylation (6, 7) and proteolytic cleavage (8, 9). Several 
IGFBPs are found in cell surface-associated (5 ,  10) as well as 
secreted forms. 
Previously, we have shown that expression of IGF I1 and 
its receptor  increase  during C2 myoblast differentiation (11- 
13)  and have demonstrated through use of antisense oligo- 
nucleotides that IGF I1 functions  in an autocrine or paracrine 
manner  in promoting C2 cell differentiation  (14). In  the course 
of these  studies, we identified an -29-kDa IGFBP that also 
was secreted  during C2 myoblast differentiation (11). Since 
IGFBPs have been shown to both  enhance and inhibit IGF 
actions ( 5 ) ,  the expression of an IGFBP during terminal 
differentiation could provide a mechanism for modulating 
IGF action  in this system. In this study, we have purified this 
IGFBP, cloned its cDNA, and identified it as the mouse 
homologue of IGFBP-5. IGFBP-5 mRNA and protein are 
expressed in C2 cells and in F3 azamyoblasts in vitro, and  its 
mRNA is synthesized in many tissues in vivo, including 
striated muscle. We also demonstrate that IGFBP-5 mRNA 
‘The abbreviations used are: IGF, insulin-like growth factor; 
IGFBP, insulin-like growth factor-binding protein; HPLC, high per- 
formance liquid chromatography; PCR, polymerase chain reaction; 
UTR, untranslated region; PAGE, polyacrylamide gel electrophoresis; 
kb, kilobase(s); BP, binding protein. 
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is found in tissues  of  non-mammalian  vertebrates and show, 
by  comparat ive protein analysis, that IGFBP-5 is  the most 
conserved IGF-binding protein identified to date. 
EXPERIMENTAL  PROCEDURES 
Materials-Tissue culture supplies (fetal bovine serum, newborn 
calf serum, horse serum, Dulbecco’s modified Eagle’s medium) were 
purchased from Life Technologies, Inc. Restriction endonucleases 
and  other enzymes (Taq polymerase, Sequenase, SP6 RNA polym- 
erase, Moloney murine leukemia virus reverse transcriptase) were 
obtained from  various manufacturers (American Allied Biochemical, 
Life Technologies, Inc., Perkin-Elmer  Cetus  Instruments, U. S. Bio- 
chemical  Corp., New England Biolabs, Promega-Biotec). Radio- 
nuclides were purchased from Du Pont  NEN  or  Amersham Corp. 
TABLE I 
Purification of a mouse IGFBP from C2 cell-conditioned media 
Purification step Estimated” total protein 
w 
C2 cell-conditioned  media 1,470’ 
Ammonium sulfate  ractionation 1,250 
Phenyl-Sepharose  chromatography 275 
Sephadex G-150 chromatography 17.9 
IGFI  affinity  chromatography 0.34 










Protein recovery was quantitated by either  direct  protein  assay 
One  unit of activity is defined as  the  amount necessary to achieve 
Estimated based on  approximately 1.4 mg/ml protein  in 2% horse 
or  absorbance a t  214 or 280 nM. 
half-maximal binding in an  IGF  binding assay. 
serum. 







FIG. 1. Analysis of purified C2  cell IGF-binding protein. 
HPLC fractions were subjected to 12.5% PAGE and either silver 
stained (A), or transferred to a nitrocellulose filter and incubated 
with ’251-labeled IGF I (B),  or a 1:lOOO dilution of an  antiserum raised 
against human IGFBP-5 (C). The ligand and immunoblot experi- 
ments were performed on  different  lanes from the  same gel, whereas 
analogous fractions  from a different  HPLC  fractionation were silver- 
stained. 
0 1 2 3 
Cell Cultures-Mouse C2 myoblasts (15)  and F3 azamyoblast clone 
b (16) were plated a t  5 X lo3 cells/ml  on  gelatin-coated 15-cm diameter 
tissue culture dishes and grown in medium containing 10% fetal 
bovine serum  and 10% newborn calf serum.  Upon attaining -80%  of 
confluent  density, cells  were  washed  with  Earle’s  balanced salt solu- 
tion, and the media were replaced with a differentiation medium 
containing Dulbecco’s modified Eagle’s medium plus 2% horse  serum. 
Differentiation medium  conditioned for 48-72 h (1050 ml) was col- 
lected and used for protein purification.  Cells used for RNA  isolation 
were harvested a t  -80% of confluent  density  and  after 2, 4, 12, 24, 
48 or 72 h of exposure  to  differentiation medium. At each  time point, 
medium conditioned by parallel cultures was  collected, and  the cul- 
tures refed. All medium samples were clarified by  low speed centrif- 
ugation and  stored a t  -20 “C until use. 
Protein Purification-Materia1 from the  supernatant  after addition 
of ammonium  sulfate  to 25% (w/v) was collected and  precipitated by 
bringing  the NHISOB concentration  to 75%, followed by centrifuga- 
tion. The pellet was redisolved in 50 mM Tris-HC1, pH 7.4, 10% 
ammonium  sulfate  (w/v).  The  sample was applied twice to a  phenyl- 
Sepharose column (3 cm X 4.4 cm), which had been  equilibrated in 
the  same buffer. Fractions that eluted in 0.02 M Tris-HC1, pH 9.0, 
contained  IGF  binding  activity when  assayed by polyethylene glycol 
precipitation (17). These fractions were lyophilized, extracted with 
0.5 M acetic acid, pooled, and applied to a G-150 Sephadex  column 
equilibrated with 0.5 M acetic acid. Active fractions determined by 
IGF  binding  assay  as above were lyophilized, extracted with 0.05 M 
Tris-HC1, pH 6.4, pooled, and applied to  an  IGF I affinity column 
equilibrated  with the  extraction buffer. Active fractions  eluted in 0.5 
M acetic acid were assayed by polyethylene glycol precipitation  assay 
and chromatographed through a C-4 reverse phase HPLC column 
(4.6 mm X 2.5 cm) (Vydac, Hesperion, CA) using an acetonitrile 
gradient. Two incompletely separated  peaks  eluted a t  -26% aceto- 
nitrile. This  fraction  contained two bands  on a silver-stained 12.5% 
PAGE  (see Fig. LA). Samples from each  band were subjected to  direct 
amino acid sequencing and to digestion with trypsin followed by 
sequencing (18). Both  protein  bands  demonstrated  the  same limited 
amino acid  sequences. 
Ligand and Western  Blotting-HPLC fractions or conditioned 
medium were electrophoresed through 12.5% PAGE  under nonreduc- 
ing conditions. Samples were transferred to nitrocellulose using a 
semi-dry electroblotter as described by Hossenlopp et al. (19). For 
ligand  blot, filters were hybridized  with 650,000 cpm (150,000 cpm/ 
ml) of ‘2sII-labeled IGF I and visualized by autoradiography. For 
Western  blot,  filters were probed with guinea pig antiserum raised 
against fragments of human  IGFBP-5  as described elsewhere (18), 
followed by incubation  with  alkaline phosphatase-conjugated  rabbit 
anti-guinea pig IgG. Bands were visualized using the  Protoblot system 
immunoblotting  reagents  per manufacturer’s  direction (Promega Bio- 
tec). 
Mouse IGFBP-5: cDNA Cloning and Seguencing”nitia1 cDNA 
clones were obtained by PCR amplification of cDNA that was reverse 
transcribed  from  differentiated C2 cell mRNA by using mixed oligo- 
nucleotide primers that were designed  based on  amino acid sequences 
obtained from the purified protein (see Fig. 3). Additional  clones were 
isolated by 3’ rapid  amplification of cDNA ends  (20), using C2 cell 
cDNA as  the  template. DNA  sequences obtained from these clones 
enabled the design of specific oligonucleotide primers, which were 
used to amplify  a  cDNA  from an  F3 azamyoblast  library in X g t l O  (a 
4 5 6 kb 
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FIG. 2. Map of mouse IGFBP-5 cDNA clones. Overlapping  clones spanning -5.5 kb were obtained by PCR-based  and conventional 
screening of cDNAs synthesized  from  F3  azamyoblast  or C2 myoblast  mRNA  (see  “Experimental Procedures”). Restriction  sites for the 
following enzymes are  indicated Hind111 ( H ) ,  PstI (P), BamHI  (B),  and XhoI ( X ) .  The signal peptide  and  mature  protein  are denoted by 
the  shaded  and open boxes, respectively.  Individual cDNAs  are  indicated below the map. The hatched box denotes a  739-nucleotide  inversion 
in X5. The region that was sequenced  from  a  genomic  clone is indicated. 
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FIG. 3. cDNA sequence of mouse IGFBP-5. cDNA and genomic clones corresponding to 5561 base pairs were sequenced on both 
strands. Two in-frame  stop codons (underlined) preceding the first ATG were found in the 5’-UTR. The 5’- and 3’-UTR  are shown in lower 
case letters, and  the coding region is shown in upper case letters. The first  amino acid of the mature protein is indicated by an arrow. The 18 
cysteines conserved among most IGFBPs are shown in italicized type. Amino acids corresponding to NHz-terminal and tryptic peptide 
sequences are underlined. The stop codon is indicated by asterisks. Direct repeats  in the 3‘-UTR are denoted by double underlines. 
gif t  of Dr. Harold Weintraub) (21). This clone was then used to screen 
the F3 library by standard methods (22) but was subsequently shown 
to have -3.2-kb PCR-induced deletion. The cDNA screening resulted 
in the identification of two sets of nonoverlapping clones, which  were 
purified by successive rounds of hybridization. The gap between these 
two groups of clones could not be amplified by PCR, hence the region 
surrounding and containing this gap was sequenced from the mouse 
IGFBP-5 gene. Comparison of the nucleotide sequences of the gene 
and cDNAs revealed a 739-nucleotide inversion at  the 5’  end of one 
of the cDNA clones, X5. The correct orientation of this region  was 
determined by ribonuclease protection assay (23), using single- 
stranded cRNA probes (24) derived from cDNAs and genomic frag- 
ments. The same approach was used to establish colinearity of the 
mRNA and  the gene in the region of the gap described above. To 
obtain further 3‘ sequence, the library was rescreened with the last 
1.2 kb of A5 (see Fig. 2). Six additional cDNA clones were purified. 
cDNA and genomic fragments were subcloned into plasmid vectors 
and were sequenced on both strands by the dideoxy chain-termination 
method (25) with Sequenase, using vector-specific or cDNA-specific 
oligonucleotide primers. DNA sequence information was compiled 
and analyzed using Geneworks (Intelligenetics) and DNA Strider 1.2 
(Christian Marck, France). 
Xenopus IGFBP-5 cDNA Cloning-CDNA was synthesized from 
Xenopus skeletal muscle mRNA using Mouse murine leukemia virus 
reverse transcriptase (22). Subsequently, a fragment corresponding 
to the NH? terminus of the protein was amplified by PCR using 
primers from the mouse IGFBP-5 cDNA. 
Computer-assisted  Amino  Acid Anulysi.+”mino acid sequences of 
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FIG. 4. Northern analysis of RNA from C2 myoblasts. C2 
cells were grown to -80% confluence and induced to differentiate. 
Total RNA was isolated from undifferentiated (UD) cultures  or a t  
various  time  points  after exposure to  differentiation medium. Total 
RNA  (5 pg) was  hybridized concurrently  to 32P-labeled  DNA  probes 
for  mouse IGFBP-5  and myogenin (28).  Filters were exposed to Kodak 
XAR5 x-ray  film  for 21 h a t  -80 "C with two  intensifying screens. 
The lower panel shows  an  ethidium  bromide-stained  agarose gel of 
the  same samples. The  pictured  experiment  is  representative of three 
independent  studies. 
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FIG. 5. Ligand and immunoblot of C2 cell-conditioned me- 
dia. Media  from cultures grown in  parallel to  those  examined  in Fig. 
4 were collected at   the specified intervals  after  initiation of differen- 
tiation.  Samples were analyzed by ligand blot  using lZ5I-labeled IGF 
I (A)  or by Western  blot  using polyclonal antiserum raised against 
human IGFBP-5 (€3). The control lane represents unconditioned 
media (Dulbecco's modified Eagle's medium plus 2% horse  serum). 
These  experiments were performed in  duplicate  with  essentially  iden- 
tical results. 
rat and human IGFBP-5 and other IGFBPs were obtained from 
Genbank. Alignments and  evolutionary  relationships  among  different 
IGFBPs were established  using Geneworks. 
RNA Isolation and Analysis-Total RNA  was  extracted  from cell 
pellets  or  animal  tissues using  a modified guanidinium  thiocyanate 
method (26, 27) and  quantitated by spectrophotometry.  Samples for 
Northern  blot  analysis were  electrophoresed through 1%  agarose, 2.2 
M formaldehyde  gels and  stained with ethidium bromide to determine 
their integrity. The  RNA was UV cross-linked (Stratalinker-Strata- 
gene) following transfer  to  supported nitrocellulose by capillary  ac- 
tion. Myogenin  (28) and  IGFBPB  DNA probes  were  labeled  with [a- 
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FIG. 6. Expression of IGFBP-5 mRNA and protein during 
F3 azamyoblast differentiation. F3 azamyoblasts were grown to 
-80% confluence and induced to  differentiate.  Total RNA was iso- 
lated from undifferentiated (UD) cultures  or at various time  points 
after  exposure  to  differentiation medium.  Media were collected at   the 
same time points from parallel cultures. A, total RNA (5 pg) was 
hybridized concurrently  to 32P-labeled  DNA  probes for mouse IGFBP- 
5 and myogenin (28).  Filters were exposed to Kodak  XAR5  x-ray film 
for 21 h a t  -80 "C with  two  intensifying screens. B, ethidium bromide- 
stained agarose gel prior to transfer. C, L251-labeled IGF I ligand blot 
of cell-conditioned  media. The control  lane  contains unconditioned 
differentiation medium. These  experiments were performed in dupli- 
cate with essentially identical  results. 
32P]dATP  and [ c ~ - ~ * P ] ~ C T P  using the  random  primer method  (29). 
Hybridization was performed a t  42 "C in  the presence of 50% form- 
amide (30). cRNA probes were synthesized by in  vitro transcription 
using SP6 RNA polymerase in the presence of [cY-~'P]CTP (24). 
Hybridization occurred a t  55 "C in solution containing 50% form- 
amide (24).  After  hybridization, filters were washed in solution  con- 
taining  15 mM NaCl, 1.5 mM sodium citrate,  pH 7.0, and 0.1% SDS 
first for 15  min a t  25 'C and  then for 60 min a t  68 "C (mouse) or 
55 "C (chicken and Xenopus). Filters were exposed to x-ray film 
(Kodak  XAR5)  using  two  intensifying screens.  Signal intensities on 
the  filters were quantified using a B emission scanner  (Betagen). 
RESULTS 
Purification of an IGFBP from C2 Cell-conditioned Media- 
Confluent  cultures of C2 cells were induced to differentiate 
in medium containing 2% horse serum for 48-72 h. Condi- 
tioned  culture medium was collected, fractionated,  and chro- 
matographed  as indicated under  "Experimental Procedures" 
and  as  summarized  in  Table I. Purification was  monitored by 
assessing IGF binding  activity  and resulted in  the recovery of 






FIG. 7. Northern analysis of IGFBP-5 mRNA in adult 
mouse tissues. Total RNA (5 pg/lane) was hybridized to a 32P- 
labeled cRNA probe from IGFBP-5 clone 4-1 (upper panel). The 
>6.0-kb IGFBP-5 transcript is indicated with an arrow. C2 cell 
mRNA was used as a positive control. The filter was exposed to 
Kodak XAR5 x-ray film for 20 h at -80 "C using two intensifying 
screens. The lower panel shows the ethidium bromide-stained gel 
prior  to  transfer. 
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FIG. 8. Northern analysis of IGFBP-5 mRNA in chicken 
and Xenopus tissues. Total  RNA was  isolated from  tissues of 7- 
week post-hatch  chicks  and from adult frogs. Chicken (10 pg) and 
Xenopus (-25 pg) samples were hybridized to a '"P-labeled cRNA 
probe from mouse IGFBP-5 clone 4-1. C2 cell RNA (5 pg) was 
included as a control. Filters were exposed to Kodak  XAR5 x-ray  film 
a t  -80 "C using two intensifying  screens for 20 h (chicken)  or 2 h 
(Xenopus). 
-61 pg of protein. The purified protein was  visualized as two 
silver-stained  bands of M, = 29,000 and 23,000 after  electro- 
phoresis  through a 12.5% nondenaturing polyacrylamide gel 
(Fig. IA). The band of higher M, could bind IGF I1 with 
higher affinity than the band of lower molecular mass as 
estimated by Western ligand blot (Fig. lB),  although both 
proteins were recognized equivalently by polyclonal antiserum 
raised against  fragments of human  IGFBP-5  (Fig 1C). The 
NH2-terminal 20 amino acids obtained from each of these 
proteins were identical,  indicating  that  the 23-kDa band was 
truncated  at  its COOH terminus. 
cDNA Cloning-At the  time  that  the C2 cell IGF-binding 
protein was purified, the sequences of only three IGFBPs 
were  known.  We therefore used protein sequence  information 
to design mixed oligonucleotide primers  and isolated  a partial 
length cDNA by reverse transcription-PCR  (31),  using mRNA 
isolated from differentiated C2 cells. The derived protein 
sequence of this 190-nucleotide  cDNA contained several  pep- 
tides  that  matched  those  obtained from the purified  protein. 
Additional cDNAs spanning 5.5 kb of the >6.0-kb mRNA 
were cloned by both PCR-based and traditional screening 
methods from  a  cDNA  library made from differentiating  F3 
azamyoblasts  (21)  and from C2 cell RNA, as described under 
"Experimental Procedures." An uncloned  gap in  the 3' UTR 
was bridged by isolating  and  characterizing a fragment of the 
mouse gene (Fig. 2). The genomic sequences  corresponding to 
this region of the 3' UTR were shown to be contiguous  in the 
mRNA by ribonuclease protection assay.' 
DNA Sequence Anulysis-The assembled  cDNA sequence 
is presented  in Fig. 3 and  consists of 5561  nucleotides,  includ- 
ing a 5' UTR of 387 base pairs, an 816-nucleotide coding 
region, and a 3' UTR of 4358 base pairs. An open reading 
frame of 271 codons  begins with  the  first ATG in  the cDNA 
and is preceded by two in-frame stop codons. The open 
reading  frame encodes  a 19-amino acid  signal  peptide followed 
by  a  252-residue mature  protein with  a  predicted molecular 
mass of 28.4 kDa, in close agreement with the size of the 
protein as estimated by SDS-PAGE.  There was  perfect  cor- 
relation between the  amino acid  sequences  deduced from the 
cDNA and the peptides, except at SerI7', which had been 
tentatively identified as a tryptophan residue. The deduced 
amino acid  sequence of the  mature  protein  is 97%  identical 
to rat and human IGFBP-5. The protein contains 18 cys- 
teines, which are conserved among five of six IGFBPs. Unlike 
other  IGFBPs,  the  IGFBP-5  mRNA  has a very large 3' UTR 
and a long  >700-nucleotide 5' UTR?  The 3' UTR  contains a 
single direct  repeat  with 21/22 identities (Fig. 3), has several 
potential  stem loops,2 and  has heterogeneous  3' ends.' Of the 
30 potential  open  reading  frames encoded by both  strands of 
this cDNA, the  authentic  open  reading frame is the largest. 
Expression of IGFBP-5  during Myogenic Differentiation- 
IGFBP-5 expression is induced during muscle differentiation 
in vitro (Figs. 4, 5, and 6). As seen  in Fig.  4, IGFBP-5 mRNA 
is  detectable  in  proliferating C2 cells, but  steady-state levels 
increase  during  terminal differentiation.  A  rise in mRNA is 
first observed  12  h after exposure to  differentiation medium 
(lane 4 ) ,  and by 48 h (lane 6), a 10-15-fold accumulation has 
occurred. As seen  in Fig.  4, the  increase  in  IGFBP-5 mRNA 
paralleled the rise in myogenin,  a myogenic regulatory tran- 
scription  factor whose mRNA  is up-regulated during muscle 
differentiation  in vitro  (32). 
Studies of IGFBP-5  protein expression revealed a differ- 
entiation-dependent rise nearly  identical  to  its mRNA (Fig. 
5). Analysis of conditioned culture media showed the appear- 
ance of a 29-kDa band by ligand blot  during  the interval from 
4 to 12  h after  initiation of differentiation  (lane 4 ) .  Accumu- 
lation of this  protein peaked  between 24 and 48 h. Western 
* P. L. James  and P. Rotwein, unpublished observations. 
Kou  Kou, P. L. James, and P. Rotwein,  unpublished  observations. 
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FIG. 9. Analysis of IGFBP-5 amino acid sequences. A, sequence comparison of IGFBP-5 among vertebrate species. The deduced 
protein sequences for mouse, rat, human, and Xenopus (partial) IGFBP5 were aligned using Geneworks. B, evolutionary relationship among 
IGF-binding proteins. The full-length amino acid sequences of IGFBPs were extracted from  Genbank and analyzed using the tree subroutine 
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blot  analysis of the  same  filter  using  anti-IGFBP-5  antiserum 
also detected a 29-kDa band with a similar time course of 
appearance, although this method was less sensitive than 
ligand  blotting. As indicated by the  results  shown  in Fig. 5A, 
no  other  IGFBPs  accumulated  in  the media during C2 myo- 
blast  differentiation. 
IGFBP-5 also is produced by F3 azamyoblasts (Fig. 6), a 
cell line derived by myogenic conversion of fetal  fibroblasts 
(10T1/2 cell line) by 5-azacytidine  treatment  (16).  Both  BP5 
and myogenin transcripts  are  more highly expressed  in  pro- 
liferating azamyoblasts than in C2 cells (compare Figs. 4A 
and 6A), and the subsequent rise in mRNA abundance is 
lower, -%fold. IGFBP-5  protein  secretion  increased  rapidly 
during  azamyoblast  differentiation;  ligand  blot  analysis  dem- 
onstrates  the  appearance of an -29-kDa band  within 2  h of 
the  onset of differentiation (Fig. 6C),  with  peak  accumulation 
between 24 to 48 h. RNA  analyses  and  protein  studies  also 
demonstrated induction of IGFBP-5 expression during the 
terminal  differentiation of several other  fusing  rodent muscle 
cell lines.' 
Expression of IGFBP-5 in the Mouse Tissues-To deter- 
mine  potential  sites of synthesis of IGFBP-5  in  the mouse, 
total RNA from various adult tissues was extracted and 
analyzed by Northern blot. As seen in Fig. 7, the >6.0-kb 
IGFBP-5 mRNA is highly expressed in  the kidney, uterus, 
and  gastrocnemius muscle and  is  present a t  lower levels in 
several other tissues. Very little  BP5  mRNA was seen  in liver, 
a  major site of synthesis of other  IGFBPs  (33),  or in  spleen. 
IGFBP-5 mRNA Is Expressed by Non-mammalian Verte- 
brutes-Because comparative  protein  sequence  analysis  sug- 
gested that  IGFBP-5 was highly  conserved in  mammals  (see 
Refs. 34 and 35 and Fig. 9B), we asked if this  BP was present 
in  other  vertebrate species. RNA  studies  using a probe derived 
from the NH2-terminal coding region of mouse IGFBP-5 
identified  similarly  sized transcripts  in  chicken  and  Xenopus 
tissues (Fig. 8). A partial  length  cDNA was then cloned from 
Xenopus  skeletal muscle RNA  by  PCR  using oligonucleotide 
primers derived from mouse IGFBP-5. Comparison of the 
deduced amino acid sequence of this  cDNA with  mouse, rat, 
and  human  IGFBP-5 revealed  38/45 identical  residues (Fig. 
9A). Additionally, as  shown  in Fig. 9B, IGFBP-5  proteins  are 
more  conserved than  are  any  other  IGFBPs identified to  date. 
Mouse, rat,  and  human  IGFBP-5  are  97%  identical,  whereas 
amino acid sequence identity of the  rat  and  human  homo- 
logues of other  BPS  range  from only 66 to 91%. Fig. 9B  also 
indicates  that  IGFBP-5  is more similar  to  IGFBP-3  and  -6 
than  to  the  other  binding  proteins. 
DISCUSSION 
This  study shows that  the  predominant  IGF-binding  pro- 
tein secreted by differentiating C2 myoblasts is IGFBP-5. 
Expression of IGFBP-5  mRNA  increases  rapidly  during C2 
cell differentiation,  with  kinetics of accumulation  similar  to 
those of myogenin, a muscle-specific transcription factor. 
Secretion of BP5 occurs in parallel to the rise in mRNA 
expression, with increases being measurable in conditioned 
culture media within 12  h of the  onset of terminal  differentia- 
tion.  By  contrast,  other  binding  proteins  do  not  appear  to  be 
synthesized  or  up-regulated  in C2 cells. Our  experiments  also 
demonstrate  that  IGFBP-5  mRNA  is  produced  in vivo by a 
variety of mouse tissues,  including  skeletal muscle, and show 
that  this  binding  protein is highly conserved among verte- 
brates,  both  in  amino acid  sequence and  in  the large size of 
its  mRNA. 
During  the  purification of  -29 kDa  IGFBP-5  from C2 cell 
conditioned  culture media,  some  proteolysis  occurred as evi- 
denced by the 23-kDa band identified by silver staining in 
Fig. 1. The  apparent  absence of this  band  in  other  Western 
blots (Fig. 5A) may be due  to differences in  sample  prepara- 
tion, with proteolysis occurring during one of the steps in 
purification procedure. A similarly sized COOH-terminally 
truncated  protein  has been  identified in  other cell lines  (8,10, 
18). In human fibroblasts and in rat granulosa cells, this 
smaller  protein  appears  to be the cleavage product of a specific 
protease (8, 18). Thus,  it  is possible that a protease became 
activated  in  the  culture m dium or during  protein purification. 
A 23-kDa form of IGFBP-5 also was isolated from human 
osteoblasts, where it  appears  to have  mitogenic activity even 
in  the  absence of IGF I (10).  It  therefore  seems reasonable to 
postulate  that  the two forms of IGFBP-5 may have different 
actions  and  that a protease  that recognizes BP5 also may be 
secreted by differentiating C2 myoblasts. 
IGFs have been shown to promote the differentiation of 
many cell types, including muscle (2), and  it  has been sug- 
gested that  IGF 11 regulates myogenesis  in vitro (for reviews, 
see Refs. 36 and 37). IGFBP-5 may modulate  the  actions of 
IGF I1 during  differentiation,  since  BP5 expression  precedes 
the  induction of IGF I1 during myogenesis. In  this  paper, we 
show that C2 cells and  F3  azamyoblasts  both  express  IGFBP- 
5 during  differentiation.  These two cell lines  have  different 
origins: C2 cells are derived  from the  thigh muscle of 2-month- 
old mice after  crush  injury  (15),  whereas  azamyoblasts were 
cloned after  treatment of 10T1/2  fibroblasts  with  5-azacyti- 
dine  (16). Although in C2 myoblasts  the  increase  in  IGFBP- 
5 mRNA  during  differentiation  is more pronounced  than  in 
azamyoblasts (compare Figs. 4A and 6A), in both cell lines 
there  is a prompt  and  sustained  induction  in  IGFBP-5  protein 
secretion  soon  after  the  onset of differentiation (see Figs. 5A 
and  6C). Also, IGFBP-5  appears  to  be  the only IGFBP  pro- 
duced  by either cell line  during  differentiation (Figs. 5A and 
6C). In this context, we cannot explain the differences be- 
tween our  results  and  those of Ernst  et ul. (38), who did  not 
detect a  29-kDa IGFBP  on ligand blots of conditioned media 
from C2C12 cells. One possibility  may be differences  between 
C2 cells and  the C2C12 sub-line,  although we have detected 
IGFBP-5 mRNA and protein in several other muscle cell 
lines.' Alternatively, media conditioned by C2C12 cells  could 
have contained proteolytically cleaved IGFBP-5, which is 
difficult to  detect by ligand  blot  (see Fig. 1). 
The precise mechanisms by which different  IGFBPs mod- 
ulate IGF action are unknown. IGFBP-1 and -3 have been 
shown to both enhance and inhibit IGF-stimulated DNA 
synthesis  in  fibroblasts (39-41). Several IGF-binding proteins 
are capable of binding  to  the cell surface at  sites  distinct from 
either IGF receptor (18, 42). IGFBP-1 and -2 each contain 
Arg-Gly-Asp sequences  (43), which have been shown in  other 
proteins to bind integrins (44). IGFBP-3 and -5 also are 
capable of attachment  to  the  surface of fibroblasts,  although 
the  mechanism of association  has  not been  established. 
IGFBP-5  has been  shown to  bind  IGF I1 preferentially (45). 
This binding could prevent the interaction of IGF I1 with 
either  IGF  receptor, or, alternatively,  the  ability of IGFBP-5 
of the Geneworks program. The genetic distance (displayed above each branch) is estimated by comparing the number of identical residues 
in two proteins with the length of the  shorter sequence using the Unweighted Pair Group Method with Arithmetic Mean (51). This analysis 
shows that  BP5 is the most conserved IGF-binding  protein and  that it is more  closely related to  BP3  and BP6 than  to  the other IGFBPs. 
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to bind to  the cell surface (18) could direct  IGF 11 to one or 
both receptors. Binding to  the cell surface may also provide a 
mechanism by which IGFBP-5 could transduce  a signal in- 
dependent of the presence of IGF I1 in the culture medium. 
Additionally, proteolytic processing, which apparently re- 
duces the affinity of BP5 for IGFs (see Fig. I), could make 
IGFs available to their receptors. Each of these possibilities 
can be tested by modulating IGFBP-5 expression in myo- 
blasts. 
IGFs exert multiple effects on target cells. In addition to 
enhancing cellular differentiation,  they have  been shown to 
stimulate proliferation, to increase nutrient uptake, and to 
inhibit  protein breakdown (2). IGFs are highly conserved; IGF 
I has been identified in  a variety of species, from salmon to 
man (for review, see Ref. 46). IGF I1 also has been found in 
mammalian and non-mammalian vertebrates, and IGF sig- 
naling pathways have been elucidated in amphibian, avian, 
and mammalian species (reviewed in Ref. 46). Our demon- 
stration of the existence of at least one IGFBP in non- 
mammalian vertebrates  potentially indicates that modulation 
of IGF action is also an important aspect of IGF signaling. 
The presence of BP5 mRNA in the chicken eye (Fig. 8) also 
suggests that a 28-kDa IGF-binding  protein previously iden- 
tified by ligand blotting  in the vitreous humor of embryonic 
and post-hatch chicks (47) is IGFBP-5. It remains to be 
determined which of the other IGFBPs also are present in 
non-mammalian species. 
The analysis presented  in Fig. 9B shows that  IGFBP-5 is 
the most highly conserved of all known IGFBPs. There is 
97% identity among BP5 homologues in mice, rats,  and  hu- 
mans, while amino acid sequence identity for other  IGFBPs 
ranges from only 66 to 91% between rat  and human proteins. 
In addition, the deduced amino acid sequence of the NH2- 
terminal region of Xenopus IGFBP-5 indicates that  IGFBP- 
5 also is conserved among non-mammalian  vertebrates. Al- 
though the reasons for the presence of IGFBP-5 in avian  and 
amphibian species are not known, one possibility for the 
strong sequence conservation between the Xenopus and mam- 
malian-binding protein is structural, since it appears that 
more sites on IGF I are required for optimal  interaction wit% 
IGFBP-5  than are needed for binding to other  IGFBPs  (45). 
The unusual size (>6.0 kb) of the IGFBP-5 mRNA also has 
been conserved among Xenopus, chicken, mouse, rat, and 
human species (Fig. 8) (35, 48); all other known IGFBPs  are 
encoded by transcripts  that  are smaller than 2.5 kb. Sequences 
in the 3' UTR of other mammalian genes have been shown 
to affect RNA stability (reviewed in Ref. 49), while transla- 
tional regulatory elements have been demonstrated  in  both 5' 
and 3' UTRs (reviewed in Refs. 49 and 50). It is presently 
unknown whether the  untranslated regions of the  IGFBP-5 
mRNA regulate these processes. 
In summary, we have demonstrated that the -29-kDa 
JGFBP we identified previously in differentiating C2 myo- 
blasts is the mouse homologue of IGFBP-5.  Both  IGFBP-5 
mRNA and  protein  are rapidly up-regulated during myoblast 
differentiation, with kinetics of accumulation that parallel 
those of the myogenic regulatory factor myogenin. IGFBP-5 
is the most conserved of all  IGFBPs, and a Xenopus homo- 
logue has been identified. Further investigation into the func- 
tion of IGFBP-5 in myoblasts and  in  other cell types may 
provide insight into  the role of IGFBPs  in cellular develop- 
ment  and differentiation. 
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